276 related articles for article (PubMed ID: 31536685)
21. Influence of fat-free mass index on the survival of patients with head and neck cancer.
Lapornik N; Avramovič Brumen B; Plavc G; Strojan P; Rotovnik Kozjek N
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1909-1917. PubMed ID: 36437380
[TBL] [Abstract][Full Text] [Related]
22. Concurrent Chemoradiotherapy Induces Body Composition Changes in Locally Advanced Head and Neck Squamous Cell Carcinoma: Comparison between Oral Cavity and Non-Oral Cavity Cancer.
Lin YC; Ling HH; Chang PH; Pan YP; Wang CH; Chou WC; Chen FP; Yeh KY
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578846
[TBL] [Abstract][Full Text] [Related]
23. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
24. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
25. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
[TBL] [Abstract][Full Text] [Related]
26. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma.
Erul E; Guven DC; Ozbay Y; Altunbulak AY; Kahvecioglu A; Ercan F; Yesil MF; Ucdal MT; Cengiz M; Yazici G; Kuscu O; Suslu N; Gullu I; Onur MR; Aksoy S
Biomark Med; 2023 Jan; 17(2):87-99. PubMed ID: 37042459
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer.
Shirasu H; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Onitsuka T; Yurikusa T; Mori K; Yasui H
BMC Cancer; 2020 Mar; 20(1):182. PubMed ID: 32131771
[TBL] [Abstract][Full Text] [Related]
29. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study.
Kawai S; Yokota T; Onozawa Y; Hamauchi S; Fukutomi A; Ogawa H; Onoe T; Onitsuka T; Yurikusa T; Todaka A; Tsushima T; Yoshida Y; Kito Y; Mori K; Yasui H
BMC Cancer; 2017 Jan; 17(1):59. PubMed ID: 28095814
[TBL] [Abstract][Full Text] [Related]
31. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.
Jung AR; Roh JL; Kim JS; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2019 Jul; 116():98-106. PubMed ID: 31185387
[TBL] [Abstract][Full Text] [Related]
33. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Maguire PD; Neal CR; Hardy SM; Schreiber AM
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
[TBL] [Abstract][Full Text] [Related]
34. Accelerated loss of lean body mass in head and neck cancer patients during cisplatin-based chemoradiation.
Lønbro S; Gam S; Hermann AP; Hansen CR; Johansen J
Acta Oncol; 2023 Nov; 62(11):1403-1411. PubMed ID: 37589161
[TBL] [Abstract][Full Text] [Related]
35. Body composition changes in patients with head and neck cancer under active treatment: a scoping review.
Ferrão B; Neves PM; Santos T; Capelas ML; Mäkitie A; Ravasco P
Support Care Cancer; 2020 Oct; 28(10):4613-4625. PubMed ID: 32533436
[TBL] [Abstract][Full Text] [Related]
36. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
37. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
[TBL] [Abstract][Full Text] [Related]
38. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
39. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
Chang PH; Yeh KY; Wang CH; Chen EY; Yang SW; Huang JS; Chou WC; Hsieh JC
Head Neck; 2017 Oct; 39(10):1990-1996. PubMed ID: 28688124
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment fat-free mass index correlates with early death in patients with head and neck squamous cell carcinoma.
Talani C; Astradsson T; Farnebo L; Mäkitie A; Ehrsson YT; Laurell G
Head Neck; 2024 Apr; 46(4):808-818. PubMed ID: 38193618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
